Technology Detail


The Office of Technology Licensing was established in 1970 to transfer technologies developed at Stanford. Find out more about OTL's history, mission, staff, and statistics.
Contact | 
Explore Technologies



Temporally Precise, Genetically Targeted Optical Control of Neural Circuitry


Stanford Reference:

05-170


Abstract


Temporally precise, noninvasive control of neural circuitry is a long-sought goal of neuroscientists and biomedical engineers.

For this purpose, the naturally occurring algal protein Channelrhodopsin-2 (ChR2), a rapidly gated light-sensitive cation channel, was engineered by using lentiviral gene delivery in combination with high-speed optical switching to photostimulate mammalian neurons. Blue-light illumination of neurons and other cells stably expressing ChR2 resulted in large, rapid membrane depolarization, allowing remote optical control of ionic flux and cellular voltage on the millisecond scale, with brief spikes of moderate-intensity light.

This invention will enable the optical control of the electrical and ionic milieu of neurons and other excitable cells, which might facilitate the modulation of ion channels, signal transduction, neural coding, sensory and motor processing, neuropsychiatric dysfunction and interneuron modulation of circuit dynamics.

Related Technology
The inventors have also developed a technology to optically inhibit neurons (see Stanford Dockets S06-398 and S06-398A). When combined, these inventions form a complete system for multimodal, high-speed, genetically targeted, all optical interrogation of living neural circuits.




Applications


  • High-throughput cell-based screening for drugs that affect signal transduction
  • Neuromodulatory therapeutics for the treatment of neurological disorders
  • Drug dosing management in the context of diabetes and pain control

Advantages


  • Millisecond kinetics enables a thousand-times faster voltage control
  • The expression of the ChR2 channel does not affect membrane integrity and cell health
  • This method does not require synthetic chemical substrates
  • Allows genetic targeting so that specific neuron subclasses can be probed

Publications



Related Web Links



Innovators & Portfolio



Patent Status



Date Released

 10/8/2020 12:00
 

Licensing Contact


Evan Elder, Senior Licensing Associate
650-725-9558 (Mobile)
Request Info

82-008 A Monoclonal Antibody Specific For Mouse Granulocytes - RB6-8C5 and RA3-6B2
82-010 A Monoclonal Antibody Specific for the B-220 Surface Glycoprotein in Mouse (RA3-3A1)
82-011 A Monoclonal Antibody Specific for Mouse and Human B Cells

more technologies »

Related Keywords


ion channels   MD: neurology   MD: neurology: neuromodulation   drug dosing management   neuronal circuits   LS: General Therapeutic: Psychiatric Diseases   neuroscience   LS: research tool: reagent   screening   LS: general therapeutic: CNS (neurology / central nervous system)   05-170   research tool   therapeutic